Nanomedicines and Nanosimilars—Why a Robust Centralised Regulatory Framework Is Essential to Enhance Patient Safety
Michael Isles
Abstract
OPINION article Front. Pharmacol., 24 February 2022 | https://doi.org/10.3389/fphar.2021.787239
Topics & Concepts
BusinessPatient safetyProcess managementRisk analysis (engineering)MedicineHealth careEconomicsEconomic growthPharmaceutical studies and practicesInhalation and Respiratory Drug DeliveryPharmaceutical Economics and Policy